Phibro Animal Health Corporation $PAHC Shares Bought by Sei Investments Co.

Sei Investments Co. raised its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 15.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,948 shares of the company’s stock after acquiring an additional 21,339 shares during the period. Sei Investments Co.’s holdings in Phibro Animal Health were worth $8,681,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Cvfg LLC acquired a new stake in Phibro Animal Health in the first quarter valued at approximately $2,962,000. Advisors Preferred LLC acquired a new position in Phibro Animal Health in the first quarter worth about $2,931,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Phibro Animal Health in the 1st quarter valued at approximately $1,759,000. Precision Wealth Strategies LLC acquired a new stake in shares of Phibro Animal Health during the fourth quarter worth $1,568,000. Finally, Capricorn Fund Managers Ltd lifted its holdings in shares of Phibro Animal Health by 45.1% in the 1st quarter. Capricorn Fund Managers Ltd now owns 267,045 shares of the company’s stock worth $14,770,000 after purchasing an additional 82,944 shares during the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the sale, the chief executive officer directly owned 67,720 shares of the company’s stock, valued at $3,778,776. This represents a 9.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $36.33 on Monday. Phibro Animal Health Corporation has a fifty-two week low of $25.58 and a fifty-two week high of $60.08. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The business has a 50-day moving average of $32.71 and a two-hundred day moving average of $43.18. The stock has a market capitalization of $1.47 billion, a P/E ratio of 15.59, a P/E/G ratio of 0.51 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts predict that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. Phibro Animal Health’s payout ratio is 20.60%.

Analyst Ratings Changes

A number of research analysts have issued reports on PAHC shares. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Citigroup cut their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Finally, Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and an average target price of $42.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.